SecBot SecBot
8-K ·Filed Nov 5, 2026

VTVT

vTv Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 11h ago SEC0001641489-26-000035
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The key catalyst is the Phase 3 CATT1 topline data readout in mid 2027. Cash runway appears sufficient through that event. The FDA Orphan Drug Designation for HPPD may support partnering discussions but is not a near-term value driver. Monitor enrollment completion confirmation and any early efficacy signals from the ongoing Phase 2a Hybrid CATT1 study.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

VTVT drug pipeline →

cadisegliatin

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.

Price Chart

Loading chart...

Executive Summary

vTv Therapeutics reported Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M loss in Q3 2025, but the per-share loss narrowed from $1.08 due to a higher share count. The company completed enrollment in its Phase 3 CATT1 trial for cadisegliatin (166 participants randomized) and expects topline results in mid 2027. Cash of $77.2M is expected to fund operations well through that readout. The FDA also granted Orphan Drug Designation to HPPD for sickle cell disease.

Key Financial Metrics

EPS
−$0.94
Revenue
$0.00
est $0.00

Key Facts

  • Phase 3 CATT1 trial enrollment completed with 166 participants randomized; topline results expected mid 2027
  • First participant randomized in Phase 2a Hybrid CATT1 pilot study for cadisegliatin in T1D patients using hybrid closed-loop insulin systems
  • FDA granted Orphan Drug Designation to HPPD (HPP8668) for sickle cell disease
  • Cash and cash equivalents of $77.2M as of September 30, 2026, down from $88.9M at December 31, 2025
  • Q3 2026 net loss attributable to vTv shareholders was $11.6M ($0.94 per share) vs $8.7M ($1.08 per share) in Q3 2025
  • RD expenses $7.5M in Q3 2026 vs $7.0M in Q3 2025, driven by Phase 3 CATT1 investment

Financial Impact

Net loss of $11.6M in Q3 2026, cash burn of ~$11.7M from $88.9M to $77.2M over nine months; no revenue in the quarter

cashnet lossrd expenses

Risk Factors

  • Phase 3 CATT1 topline results are binary and not expected until mid 2027
  • Cash burn rate may require additional financing before or after the readout if results are negative
  • No revenue from product sales; company is entirely dependent on clinical trial outcomes and partnership income

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001641489-26-000035
Document: vtvt-20261105.htm0001641489-26-000035
Document: 0001641489-26-000035-index-headers.html0001641489-26-000035
Document: 0001641489-26-000035-index.html0001641489-26-000035
Document: 0001641489-26-000035.txt0001641489-26-000035
8-K Data (Synthetic)0001641489-26-000035

US Market Status

Market Closed · Opens in 5h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026